Seoul, South Korea

Geunho An

This inventor holds 1 USPTO granted patent. Top assignee: Nexel Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Geunho An. Retrieved from https://idiyas.com/inventor/geunho-an

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Geunho An: Innovator in Pulmonary Fibrosis Treatment

Introduction

Geunho An is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of medicine, particularly in the treatment of idiopathic pulmonary fibrosis. His innovative work has led to the development of a unique pharmaceutical composition aimed at addressing this challenging condition.

Latest Patents

Geunho An holds a patent for a "Polypeptide for Preventing or Treating Idiopathic Pulmonary Fibrosis and Pharmaceutical Composition Containing the Same." This patent represents a crucial advancement in therapeutic options for patients suffering from this disease. With 1 patent to his name, An's work is paving the way for new treatment methodologies.

Career Highlights

An is currently employed at Nexel Co., Ltd., where he continues to push the boundaries of medical research and innovation. His role at the company allows him to collaborate with other talented professionals in the field, enhancing the impact of his work.

Collaborations

Throughout his career, Geunho An has worked alongside esteemed colleagues such as Choongseong Han and Donghun Woo. These collaborations have fostered a dynamic environment for innovation and have contributed to the success of their projects.

Conclusion

Geunho An's contributions to the field of pulmonary medicine are noteworthy and reflect his dedication to improving patient outcomes. His innovative patent and collaborative efforts position him as a key figure in the ongoing fight against idiopathic pulmonary fibrosis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…